Abstracts controlled trials; and 3) previous pharmacoeconomic OAB studies. Due to lack of variance for success rate in published reports, sensitivity analyses used +/-50%. RESULTS: Success rates for the treatments were 35.6%(OxyIR), 23.0%(OxyER), 39.0%(OxyTD), 24.6%(TolIR), and 16.8%(TolER). Cost per complete continence was lowest for OxyIR ($5777), followed by OxyTD ($6189), TolIR ($8658), OxyER ($9121), and TolER ($11,850) . OxyER, TolIR, and TolER were dominated by OxyIR and OxyTD. Comparing OxyIR, use of OxyTD was an additional $9916 per person with complete continence. Sensitivity analyses found that success rate was the key parameter driving the analysis. When the success rate of OxyIR varied from 17.8% to 53.4%, the ICER of OxyTD changed from $1462 to being dominated. When the success rate of OxyTD varied from 19.5% to 58.5%, the ICER of OxyTD changed from being dominated to $1151. Sensitivity analyses of other model parameters were found to not change the rank orders of treatments. CONCLU-SION: The results of this study suggested OxyIR is the most cost-effective treatment for overactive bladder among various preparations of oxybutynin and tolterodine. The second costeffective agent is OxyTD.
PUK7 ESTIMATING THE COST SAVINGS DUE TO THE EFFECT OF KREMEZIN IN DELAYING THE ONSET OF RECEIVING DIALYSIS TREATMENTS AMONG PATIENTS WITH CHRONIC RENAL FAILURE
Kang HY, Cho WH, Lee SM, Lee HY, Kim HJ, Moon YO Yonsei University, Seoul, South Korea OBJECTIVE: To evaluate the economic value of a pharmaceutical product, Kremezin, in treating patients with chronic renal failure (CRF) by estimating the amount of cost savings due to its effect of delaying the onset of receiving dialysis treatments. METHODS: The types of costs included were direct medical and non-medical costs, and productivity loss costs. The information about the effect of Kremezin was obtained from the results of randomized controlled clinical trials. Cost information was derived from administrative data for 20 hemodialysis and 20 peritoneal patients from one tertiary care hospital, and 20 hemodialysis patients from one free-standing dialysis center. Percapita cost savings resulting from Kremezin therapy were separately estimated for the cases delaying the onset of hemodialysis and the cases for peritoneal dialysis. By computing the weighted average for the cases of hemodialysis and peritoneal dialsyis, the expected per-capita cost savings of a patient with CRF was obtained. Using the discount rate of 5%, future cost savings were converted to the present value. Budget impact analysis was performed to estimate the expected national cost savings if Kremezin is administered to 25%, 50%, and 75% of the total incident dialysis patients in 2004. RESULTS: Depending on the effect of Kremezin in delaying the onset of dialysis treatments by one, two, or four years, a patient with CRF could save costs by 1.8¢ 5.5, 1.6¢ 5.1 and 3.4¢ 10.6 million Korean Won (KW), respectively from the perspectives of insurer, patient, and society. Also, the national financial impact of adopting Kremezin for 25%, 50%, and 75% of the total incident dialysis patients was estimated as cost savings of about 61,511¢ 579,162 million KW per year in Korea. CONCLUSION: The estimated amount of cost savings resulting from treating CRF patients with Kremezin confirms that its effect of delaying the onset of dialysis treatments has a considerable economic value.
PUK8 THE DIRECT COSTS OF STRESS URINARY INCONTINENCE TREATMENT AMONG WOMEN IN A MEDICAID POPULATION
Kinchen K 1 , Chang S 2 , Girts TK 3 , Long S 4 , Pantos B 1 1 Eli Lilly and Company, Indianapolis, IN, USA; 2 Medstat, Inc, Washington, DC, USA; 3 Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA; 4 Medstat, Inc, Hampden, ME, USA OBJECTIVE: To describe treatment utilization and associated costs for women diagnosed with stress urinary incontinence in a Medicaid population. METHODS: We utilized a pooled database consisting of health care claims for women enrolled in Medicaid in one of four states. After identifying women with a coded diagnosis consistent with stress urinary incontinence (SUI), treatment utilization and costs were determined for the 12 months after the urinary incontinence diagnosis. RESULTS: Of the 13,672 women with a diagnosis of SUI, average urinary incontinence-related costs were approximately $800 in the 12month study period, accounting for less than 0.1% of total Medicaid spending. Approximately one-third of the SUI patients received an anticholinergic medication in the study period, though these medications are not indicated for SUI treatment. A total of 13% of women underwent a surgery for SUI in the study period, with sling procedures performed most commonly. Mean UI-specific costs in the study period for the surgical and nonsurgical SUI patients were $3258 and $424 (p < 0.001) respectively. CONCLUSIONS: While overall population estimates of the prevalence of any stress urinary incontinence symptoms often are high, diagnosis and treatment utilization in the Medicaid population is low, and overall costs of SUI treatment in Medicaid currently are minimal. Further efforts to understand the appropriate detection, diagnosis, and treatment of women with SUI are needed.
PUK9 INTERSTITIAL CYSTITIS COSTS,TREATMENT AND COMORBIDITIES IN AN EMPLOYED POPULATION
Wu EQ 1 , Birnbaum H 1 , Parece A 1 , Kang YJ 1 , Mareva MN 1 , Taitel H 2 1 Analysis Group, Inc, Boston, MA, USA; 2 Ortho-McNeil Pharmaceuticals, Raritan, NJ, USA OBJECTIVES: This study assessed per patient direct medical costs and indirect work loss of diagnosed interstitial cystitis ("IC") patients from an employer's perspective. Treatment pattern of IC was also assessed. METHODS: Patients under age 65 with at least one IC diagnosis (n = 749) were drawn from a de-identified, administrative database of approximately twomillion beneficiaries that includes medical, drug, and disability claims for 1999-2002. A 2 : 1 matched non-IC control sample was randomly selected based on matching demographic characteristics (i.e. age, gender, region of residence). Annual costs and comorbidities were compared between IC and the non-IC samples descriptively. A multivariate two-part regression model was applied to estimate IC excess medical costs and indirect work loss costs while adjusting for observed patient demographics and comorbidities. All costs were adjusted to 2002 USD using Consumer Price Index ("CPI"). Intent-to-treat approach was adopted to profile treatment patterns of IC. RESULTS: An average IC patient had 130% higher direct medical costs ($3756) and 80% higher indirect costs ($725) than a non-IC patient. Compared with non-IC patients, IC patients had higher diagnostic prevalence of prostatitis (Relative Risk ("RR") = 40.0, P < 0.05), endometriosis (RR = 7.4, P < 0.05), vulvodynia (RR = 6.9, P < 0.05), chronic pelvic pain (RR = 5.8, P < 0.05), and urinary tract infections (RR = 5.1, P < 0.05). IC patients were also more likely to suffer from depression (RR = 2.8, P < 0.05)
